Condition: Pancreatitis, Chronic · Pancreatitis, Acute · Diabetes Mellitus · Sponsor: Mayo Clinic
The purpose of this study is to evaluate efficacy of pioglitazone (PIO) versus empagliflozin (EMPA) to improve glycemic control in people with Chronic Pancreatitis (CP) or Recurrent Acute Pancreatitis (RAP) associated with Diabetes Mellitus (DM). To evaluate mixed meal response in PIO versus EMPA group to better understand physiology of both therapies in CP-DM.
This description comes directly from the study's public registry record.
Ravinder Jeet Kaur, M.B.B.S · 507-255-1455 · Kaur.ravinder@mayo.edu
Always discuss trial participation with your own doctor first.
| Mayo Clinic | Rochester, Minnesota, United States | Recruiting |
| University of Pittsburgh Medical Center | Pittsburgh, Pennsylvania, United States | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06729996